MX2015007185A - Uso de eribulina en el tratamiento de cancer de pecho. - Google Patents

Uso de eribulina en el tratamiento de cancer de pecho.

Info

Publication number
MX2015007185A
MX2015007185A MX2015007185A MX2015007185A MX2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A
Authority
MX
Mexico
Prior art keywords
breast cancer
eribulin
treatment
subjects
provides methods
Prior art date
Application number
MX2015007185A
Other languages
English (en)
Inventor
He Yi
Kremer Alton
Tarassoff Peter
Olivo Martin
Matthew Guo D
Savulsky Claudio
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015007185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2015007185A publication Critical patent/MX2015007185A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

La invención provee métodos de tratar cáncer de pecho en sujetos que tienen cáncer de pecho diseminado localmente o metastásico.
MX2015007185A 2012-12-04 2013-12-04 Uso de eribulina en el tratamiento de cancer de pecho. MX2015007185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733238P 2012-12-04 2012-12-04
US201361878204P 2013-09-16 2013-09-16
PCT/IB2013/002911 WO2014087230A1 (en) 2012-12-04 2013-12-04 Use of eribulin in the treatment of breast cancer

Publications (1)

Publication Number Publication Date
MX2015007185A true MX2015007185A (es) 2017-09-05

Family

ID=50031376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007185A MX2015007185A (es) 2012-12-04 2013-12-04 Uso de eribulina en el tratamiento de cancer de pecho.

Country Status (11)

Country Link
US (1) US20140163095A1 (es)
EP (1) EP2928464A1 (es)
JP (2) JP6466339B2 (es)
KR (1) KR20150090921A (es)
AU (2) AU2013353745A1 (es)
BR (1) BR112015012731A2 (es)
CA (1) CA2892780A1 (es)
IL (1) IL239007B (es)
MX (1) MX2015007185A (es)
RU (1) RU2689977C2 (es)
WO (1) WO2014087230A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3587408A1 (en) 2004-06-03 2020-01-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin b
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
JP6644479B2 (ja) * 2014-06-24 2020-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016141209A1 (en) * 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
SG11201907217RA (en) * 2017-02-20 2019-09-27 Polyphor Ag Pharmaceutical combinations for treating cancer
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
EP3713565A1 (en) * 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CA3090479A1 (en) * 2018-02-05 2019-08-08 Tesaro, Inc Pediatric niraparib formulations and pediatric treatment methods
WO2020097625A1 (en) * 2018-11-09 2020-05-14 G1 Therapeutics, Inc. Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP2277873B1 (en) 1998-06-17 2012-05-30 Eisai R&D Management Co., Ltd. Intermediate compound for the preparation of halichondrin analogs
EP3587408A1 (en) 2004-06-03 2020-01-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin b
PL1853250T3 (pl) * 2005-02-18 2012-03-30 Abraxis Bioscience Llc Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona
CA2922029C (en) * 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
CN101883763B (zh) 2007-10-03 2016-04-20 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
JP6001857B2 (ja) 2008-04-04 2016-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンｂ類似体
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
SG193489A1 (en) * 2011-03-18 2013-10-30 Eisai R&D Man Co Ltd Methods and compositions for predicting response to eribulin

Also Published As

Publication number Publication date
AU2013353745A1 (en) 2015-06-11
IL239007B (en) 2018-04-30
JP2019089776A (ja) 2019-06-13
EP2928464A1 (en) 2015-10-14
AU2018214086A1 (en) 2018-08-23
KR20150090921A (ko) 2015-08-06
AU2018214086B2 (en) 2020-07-09
RU2015126539A (ru) 2017-01-13
WO2014087230A1 (en) 2014-06-12
RU2689977C2 (ru) 2019-05-30
JP6678783B2 (ja) 2020-04-08
JP2016501213A (ja) 2016-01-18
IL239007A0 (en) 2015-07-30
CA2892780A1 (en) 2014-06-12
JP6466339B2 (ja) 2019-02-06
US20140163095A1 (en) 2014-06-12
BR112015012731A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
IL263678B (en) Compounds for use in the treatment of breast cancer +ar
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
EA201400178A1 (ru) Лечение рака молочной железы
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2016014007A (es) Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab.
IL276733A (en) Use of Aribolin in cancer treatment
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016000131A (es) Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
HUE054998T2 (hu) Kombinációs terápiák emlõrák kezelésében való alkalmazásra
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
IL269121A (en) Usl-311 for use in the treatment of cancer
IL252639A0 (en) Breast cancer treatment using taxane
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment